



ERA CoBioTech (ERA-Net Cofund on Biotechnologies)


ACHEMA2018

Kick-off session: "Biotechnology  
for a sustainable bioeconomy"

Title: ComRaDes


Project name: COMputation for RAtional DESign:  
From lab to industry with success

Name: Henk Noorman



This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant 722361

Frankfurt am Main, 13.06.2018



SINOCHEM



DSM

DSM Sinochem Pharmaceuticals


- Partners:
  - DSM Sinochem Pharmaceuticals, NL
  - Technical University Delft, NL
  - University Liege, B
  - Syngulon, B
  - University Stuttgart, D

- Total project budget: 2 M€

- Project start: July 25, 2018

TU Delft

LIEGE université

Gembloux  
Agro-Bio TechSYNGULON  
Microbial  
fermentation  
technologies  
for bio-based  
productsUniversität  
Stuttgart

- Sustainable production and conversion of different types of feedstocks and bioresources into added value products
- Scientific approaches:
  - Synthetic biology
  - Systems biology
  - Bioinformatic tools
  - Biotechnological approach(es)

Project objectives (problem to be solved):

- Moving to bio-based economy
- Use of microorganisms to convert renewable feedstocks into added-value products




Figure 3 – Analogous Model of a Biobased Product Flow-chart for Biomass Feedstocks

● Project objectives (problem to be solved):

- Moving to bio-based economy
- Use of microorganisms to convert renewable feedstocks into added-value products

**Titer  
Rate  
Yield**

**Productivity (g/l.h)**

Lactic acid: 150 (cell recycling)  
 Ethanol: 82 (ISPR, cell recycling)  
 Sorbitol: 38  
 Gluconate: 19 (cell retention, pure O<sub>2</sub>)  
 Succinate: 15 (cell retention, ISPR)  
 1-butanol: 10 (immobilized cells)  
 Valine: 6 (metabolic engineering)


**Yield (g/g, % of max)**

Lactic acid: 1.00 (~100%)  
 Citric acid: 0.88 (80%)  
 Acetic acid: 0.80 (80%)  
 Glutamate: 0.60 (80%)  
 Ethanol: 0.51 (96%)  
 Lysine: 0.44 (74%)  
 1-Butanol: 0.36 (85%)  
 Methane: 0.27 (~100%)

**Titer (g/l)**

Gluconate: 504  
 Sorbitol: 300  
 Xylitol: 244  
 Erythritol: 240  
 Citric acid: 240  
 Mannitol: 237  
 Lactate: 231  
 Valine: 227  
 Acetic acid: 203  
 Ethanol: 170  
 2,3 Butanediol: 152  
 Succinate : 146  
 1,3-Propanediol: 141  
 Glutamate: 141  
 Threonine: 118  
 1,4 Butanediol: 115

**Published best key performance  
 Indicators of commercial products**



- Project objectives (problem to be solved):
  - Moving to bio-based economy
  - Use of microorganisms to convert renewable feedstocks into added-value products
  - Takes long time (5 years), costly (10 M€)

- Project objectives (problem to be solved):
  - Moving to bio-based economy
  - Use of microorganisms to convert renewable feedstocks into added-value products
  - Takes long time (5 years), costly (10 M€)
  - Bottleneck of bringing synthetic biology innovations to the factories



Scale-up


Lab vs. Industry:

*Conditions not the same!*

Scale-down



- Project objectives (problem to be solved):
  - Moving to bio-based economy
  - Use of microorganisms to convert renewable feedstocks into added-value products
  - Takes long time (5 years), costly (10 M€)
  - Bottleneck of bringing synthetic biology innovations to the factories



Scale-up fail

Lab vs. Industry:

*Conditions not the same!*






- Project objectives (problem to be solved):
  - Moving to bio-based economy
  - Use of microorganisms to convert renewable feedstocks into added-value products
  - Takes long time (5 years), costly (10 M€)
  - Bottleneck of bringing synthetic biology innovations to the factories

## Bioprocess Development must become


- Cheaper: 10 M€ → 2 M€
- Faster: 5 y → 1 y
- Better: TRY (titer, rate, yield) closer to the maximal possible
- Less risky: no full-scale problems



# Introduction


## Lagrangian CFD approach

- Scientific approach: High-precision scale-down and improved scale-up performance via computation-driven, rational design



- Track many microbes, register their adventures
  - Developed by Lapin and Reuss (2004, 2006)

*Track  $\sim 10^3 - 10^5$  particles*  
*Record “Lifelines”*




*Glucose uptake ( $q_s$ ) from the organism point of view*


# Introduction

## Industry to lab: lifeline scale-down



1. Simulate reactor, collect lifelines




2. Analyze lifelines:  
Fluctuation statistics




3. Invert statistics:  
Scale-down design




## Impact of multiple sources of extracellular (bioreactor) noise



Sugar concentration and uptake rate



Oxygen concentration and uptake rate





Shear rate gradients


Cumulative effects - intensified impact




## Impact of extracellular (bioreactor) noise on intracellular (biological) noise




t = 0 min



t = 50 min



t = 100 min



**Colony 1** with heterogeneous GFP expression

**Colony 2** without GFP expression

## Work package structure

**WP 0 - Overall coordination: Delft/Noorman, supported by DSP/van de Sandt**

Large-scale bioreactor data, research strain *S. cerevisiae*, methods, knowhow, LCA input

DSP\*: large-scale bioreactor data, research strain *P. chrysogenum*, methods, knowhow, LCA input

\* DSM Sinochem Pharmaceuticals

DSM: coordination  
WP Integration  
Ethical/societal aspects  
Exchange of students  
Project management  
Reporting

**WP 4 – Characterization of microbial population dynamics in large scale-conditions: Liege/Delvigne**

Syngulon: Strain evolution and synthetic biology

Scale-up to pilot  
Validation

Single cell/population modeling and experiments  
Selected scale-down experiments

**WP 1 – Computation and scale-down design for industrial fermentors: Delft/Noorman**

Transfer validated models to industry

Euler-Lagrange large-scale computation (two systems), including gas phase, kinetics  
Design of scale-down simulators

**WP 2 – Development and validation of compact biological reaction kinetic models: Delft/vGulik**

Kinetic/structured modeling  
Single reactor scale-down experiments  
Use of 'omics' diagnostic tools  
Strain evolution/synthetic biology

**WP 3 – Studying large-scale conditions by wet- and dry-lab approaches: Stuttgart/Takors**

Euler-Lagrange computation, including cell population modeling  
Kinetic/structured modeling  
Dual reactor scale-down experiments



Penicillium chrysogenum



Saccharomyces cerevisiae

**P1 DSM Sinochem Pharmaceuticals  
/ van de Sandt**

**Linked 3rd party: DSM Food Specialties  
/ Noorman**


**P4 TU Delft  
/ van Gulik**

**P2 U Stuttgart  
/ Takors**

**P4 TU Delft  
/ Noorman**

**P3 U Liège  
/ Delvigne**


**P5 SYNGULON  
/ Gabant**



- 1: *P. chrysogenum* strains
- 2: industrial conditions
- 3: *S. cerevisiae* strains
- 4: industrial conditions
- 5: *cfd* approaches
- 6: kinetic models
- 7: metabolomics data
- 8: proteomics data
- 9: engineering of robust strains
- 10: analysis of population heterogeneity

Data exchange via FAIRDOMhub

**Outcome:**  
*Ab initio, in silico* scale-up design



- Data management plan: Will be hosted by the DSM data platform with back-up at TU Delft
- Dissemination & Communication Manager: Prof. Frank Delvigne, covering following activities:
  - establishing and updating dissemination and outreach strategy, plan and dissemination;
  - dealing with open access to publications;
  - giving support while implementing the communication activities;
  - networking and community building;
  - raising target groups awareness about project results.




● *Outcomes to be achieved:*


- accelerating the bioprocess development including plant start-up by at least 20% (e.g. from 5 to 4 years), which could after 10 years further develop into a factor 5 (from 5 to 1 year).
- developing guidelines for constructing strains such that they are robust enough for harsh production conditions
- the early identification of scale-up sensitive properties of novel producers to ensure efficient use of manpower and research capacities
- reducing of the order of 10's of tonnes of CO<sub>2</sub> emission per large-scale fermentation
- reducing the energy requirements of at least 10%, i.e. in the order of 10 MWh, per run executed on industrial scale
- reducing by at least 20% the development budget (e.g. from 10 M€ to 8 M€), which could after 10 years further advance to a factor 5 (from 10 to 2 M€)

- *Planned implementation and exploitation of results:*

The projects should fall within TRL<sub>3-6</sub>: ComRaDes uses two real life examples to develop and demonstrate its approach. Its final delivery is a working framework, that can be used by industry not only for the two cases used but in principle for 'any' engineered micro-organism and its application in sustainable biotech. The research part of ComRaDes is at TRL 3-4, the final delivery at TRL 5-6. The presence of DSM Sinochem Pharmaceuticals as active partner in our consortium guarantees focus on reaching TRL 6, i.e. demonstrating our approach on existing processes from industry.

# Artist impression






SINOCHEM



DSM Sinochem Pharmaceuticals



LIÈGE université

Gembloux  
Agro-Bio TechUniversität  
Stuttgart

- Coordinator: Henk Noorman, [henk.noorman@dsm.com](mailto:henk.noorman@dsm.com)
- Partners:
  - Emile van de Sandt, DSM Sinochem Pharmaceuticals, NL
  - Walter van Gulik, Technical University Delft, NL
  - Frank Delvigne, University Liege, B
  - Philippe Gabant, Syngulon, B
  - Ralf Takors, University Stuttgart, D

